Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Tuesday, July 1
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Investing»Investing in Data Optimizes AI in Manufacturing
    Investing

    Investing in Data Optimizes AI in Manufacturing

    October 16, 20243 Mins Read


    Artificial intelligence could revolutionize cell therapy manufacturing, but the industry needs to get better at gathering and handling data according to an expert, who says companies must stop creating silos.

    Making a cell therapy is a technically challenging process that combines complicated genetic modification and culturing steps. Each process has variables that must be monitored and controlled.

    At present, rather than looking at entire processes, most manufacturers tend to collect and analyze data at each unit operation. While this approach affords control over the processing step in question, it also creates silos that limit data use, says Dalip Sethi, PhD, commercial leader, cell therapy technologies at Terumo Blood and Cell Technologies.

    “AI holds significant promise in the cell therapy and biopharma sectors to improve efficiency, reduce waste, cut costs, and enhance outcomes. However, the industry is still in the early stages of determining which manufacturing parameters most impact patient outcomes and how best to optimize them.”

    “A key barrier is access to reliable data. The industry’s tendency to silo data complicates AI’s ability to learn from it. While advanced automated technologies are available, adoption has been slow. Early-stage developers often rely on manual processes, limiting digital data capture, and large datasets for model training remain scarce,” he tells GEN.

    Rather than investing in AI systems upfront, cell therapy companies that want to embrace the approach and make the best use of process data need to focus on their IT and monitoring systems, Sethi says.

    “To implement AI in manufacturing, cell therapy and drug firms need a robust infrastructure focused on comprehensive data capture throughout key processes like cell collection, logistics, and therapy manufacturing.”

    Cell culture is a good example of an area that could benefit from AI optimization with the right monitoring and data management infrastructure in place, Sethi says.

    “By integrating biosensors for real-time monitoring, researchers can gather data on essential environmental conditions. With more data on metabolic markers like lactate and glucose, automated platforms can eventually predict cell counts and the ideal time for harvesting, creating more efficient and scalable manufacturing systems.”

    “However, the key challenge remains collecting enough data to train the computational models and fully optimize the processes.”

    Despite these challenges, Sethi is confident the potential benefits of AI will eventually see more developers invest in the data systems required.

    “In the rapidly advancing cell and gene therapy field, embracing AI and machine learning is becoming essential for transforming manufacturing processes. Data collection across the entire value chain plays a pivotal role, and leveraging enabling technologies can provide deeper insights into these processes. As automation continues to expand in manufacturing, integrating various platforms and the data they generate becomes increasingly crucial.”





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleBitcoin bulls eye $70,000 near record-high on optimism around riskier assets ahead of US elections
    Next Article Bitcoin hits highest level since July, boosting crypto-related stocks

    Related Posts

    Investing

    Analyses et prévisions relatives aux crypto-monnaies

    June 29, 2025
    Investing

    Les États-Unis peuvent-ils mettre fin à leur dépendance vis-à-vis de la Chine pour les terres rares avant qu’il ne soit trop tard ?

    June 9, 2025
    Investing

    Tesla corrige après un rallye de 23% en mai : Faut-il craindre un déclin durable ?

    June 5, 2025
    Leave A Reply Cancel Reply

    Top Posts

    Action Ganglong China Property Group Limited | Cours 6968 Bourse Hong Kong S.E.

    July 31, 2007

    les fondamentaux de l’or restent bons

    September 4, 2007

    les fondamentaux de l’or restent bons

    September 4, 2007
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Finance

    Hedge fund study on U.S. Treasury issuance fuels debate

    July 26, 2024
    Stock Market

    Shunning home markets, South Korean retailers pile-up on US stocks

    August 14, 2024
    Commodities

    Oil set for 3% weekly gain on easing recession concerns, rising Mideast tension By Reuters

    August 9, 2024
    What's Hot

    Utilities Up on Defensive Bias — Utilities Roundup

    March 26, 2025

    Trive Property nomme Lau Tong Hwee au poste de directeur exécutif

    April 22, 2025

    Texas governor gives utility deadline to resolve ongoing power outages

    July 16, 2024
    Most Popular

    What XRP Price Could Be if Bitcoin Expands to $52.3M

    August 19, 2024

    Here’s Why Bitcoin (BTC) Is Likely Mirroring 2019 Price Action, According to Analyst Benjamin Cowen

    August 19, 2024

    Knight Frank upholds forecast but awaits Budget – Mortgage Finance Gazette

    August 27, 2024
    Editor's Picks

    Commodities Prices in Bengaluru – May 3: Rediff Moneynews

    May 3, 2025

    S&P/TSX composite rises Wednesday, U.S. stock markets coast after inflation report

    August 14, 2024

    War on ESG investing must shift focus to proxy advisers

    August 10, 2024
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2025 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.